Contract Service Providers Gear Up to Develop Emerging Therapies
Technology advances enable contract service providers to keep pace with the demands of existing and emerging biologic-based therapies.
Technology advances enable contract service providers to keep pace with the demands of existing and emerging biologic-based therapies.
The panelists in this roundtable discussion included: John Allinson, head of biomarker strategy, drug development services at LGC; Martha S. Rook, head of novel therapies, process solutions, MilliporeSigma; Joe Codamo, general manager, Patheon; Brian Hampson, Vice-President, Global Manufacturing Sciences and Technology, PCT, a Caladrius Company; Stephen Gacheru, Executive Director–Biopharmaceutical Product Development, PPD Laboratories; Bruce Stauffer, Executive Director–Immunochemistry Department, PPD Laboratories; and Mark Rogers, VP USA–Life Science, SGS.
Download the
BioPharm International 2016 Outsourcing Resources eBook.
